New data evaluating safety and efficacy of Genvoya show it bests Stribild

Positive 144-week data from two Phase III studies (Studies 104 and 111) evaluating the safety and efficacy of Genvoya (elvitegravir 150mg, cobicistat 150mg, emtricitabine 200mg and tenofovir alafenamide 10mg) for the treatment of HIV-1 infection in treatment-naïve adults were announced) at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle by US biotech major Gilead Sciences (Nasdaq: GILD).

Through Week 144, Genvoya, which was approved for marketing in the USA and Europe in 2015, demonstrated significantly higher rates of virologic suppression compared to Gilead's Stribild (elvitegravir 150mg, cobicistat 150mg, emtricitabine 200mg and tenofovir disoproxil fumarate 300mg), based on the percentage of patients with HIV-1 RNA levels less than 50 copies/mL. Patients receiving Genvoya also demonstrated favorable renal and bone laboratory parameters compared to those treated with Stribild.

"As people grow older with HIV, physicians are increasingly looking for highly effective medications that may help address the evolving needs of their patients who face a lifetime of antiretroviral therapy," said Jose Arribas, Associated Professor of Medicine, Hospital La Paz, IdiPAZ, Madrid, Spain and the lead study investigator. "These study results further demonstrate that Genvoya provides durable viral suppression and has a demonstrated safety profile for long-term use by a range of appropriate HIV patients," added Dr Arribas.